Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 131 of the 136 references it cites were found in a registry or an index.

Targeting Interleukin-17 as a Novel Treatment Option for Fibrotic Diseases

Open access
Sisto, Margherita, Lisi, Sabrina · 2023 · Journal of Clinical Medicine

Abstract

Fibrosis is the end result of persistent inflammatory responses induced by a variety of stimuli, including chronic infections, autoimmune reactions, and tissue injury. Fibrotic diseases affect all vital organs and are characterized by a high rate of morbidity and mortality in the developed world. Until recently, there were no approved antifibrotic therapies. In recent years, high levels of interleukin-17 (IL-17) have been associated with chronic inflammatory diseases with fibrotic complications that culminate in organ failure. In this review, we provide an update on the role of IL-17 in fibrotic diseases, with particular attention to the most recent lines of research in the therapeutic field represented by the epigenetic mechanisms that control IL-17 levels in fibrosis. A better knowledge of the IL-17 signaling pathway implications in fibrosis could design new strategies for therapeutic benefits.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/jcm13010164

Cites

131 of 131 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Role of IL-17 cytokines in fibrotic autoimmune diseases IL-17 is produced by epithelial cells, dendritic cells, macrophages, CD4 T helper 17 (Th17), and gamma/delta T cells (Tγδ17 cells). IL-17 signaling promotes the production of pro-inflammatory factors such as granulocyte-macrophage colony-stimulating factor (GM-CSF), tumor necrosis factor (TNFα), and the release of pro-inflammatory cytokines such as IL-6, IL-8, and IL-23. These pathogenic factors exacerbate chronic inflammation and, often through the epithelial-mesenchymal transition (EMT) process, cause the fibrotic evolution of autoimmune diseases.
Figure 1 Role of IL-17 cytokines in fibrotic autoimmune diseases IL-17 is produced by epithelial cells, dendritic cells, macrophages, CD4 T helper 17 (Th17), and gamma/delta T cells (Tγδ17 cells). IL-17 signaling promotes the production of pro-inflammatory factors such as granulocyte-macrophage colony-stimulating factor (GM-CSF), tumor necrosis factor (TNFα), and the release of pro-inflammatory cytokines such as IL-6, IL-8, and IL-23. These pathogenic factors exacerbate chronic inflammation and, often through the epithelial-mesenchymal transition (EMT) process, cause the fibrotic evolution of autoimmune diseases.CC BY · PubMed Central
Figure 2 The main cellular sources and targets of IL-17A and IL-17E in the EMT-mediated fibrotic evolution of autoimmune diseases. IL-17A/E contributes to idiopathic pulmonary fibrosis, primary biliary cirrhosis, and salivary gland fibrosis through the activation of EMT, which leads to fibroblast proliferation and differentiation into myofibroblasts. EMT (epithelial-mesenchymal transition); T h17 cells (T helper 17 cells).
Figure 2 The main cellular sources and targets of IL-17A and IL-17E in the EMT-mediated fibrotic evolution of autoimmune diseases. IL-17A/E contributes to idiopathic pulmonary fibrosis, primary biliary cirrhosis, and salivary gland fibrosis through the activation of EMT, which leads to fibroblast proliferation and differentiation into myofibroblasts. EMT (epithelial-mesenchymal transition); T h17 cells (T helper 17 cells).CC BY · PubMed Central
Figure 3 The main epigenetic changes associated with differentiation of T h17 cells and upregulation of IL-17 are DNA methylation, histone post-translational modifications, and ncRNA (lncRNA and miRNAs). Bet proteins (bromodomain and extra-terminal domain); BRDs (bromodomains); DNMTs (DNA methyltransferases); ncRNA (non-coding RNA); lncRNA (long non-coding RNA); miRNA (microRNA); Dicer (Endoribonuclease Dicer C-terminal complex); TET (ten-eleven translocation); 2OG (2Oxoglutarate Oxygenase); IOX-1 (Histone demethylase inhibitor); Risc (RNA-induced silencing complex); T h17 cells (T helper 17 cells); the symbol “?” indicates that the mechanism has not yet been clarified.
Figure 3 The main epigenetic changes associated with differentiation of T h17 cells and upregulation of IL-17 are DNA methylation, histone post-translational modifications, and ncRNA (lncRNA and miRNAs). Bet proteins (bromodomain and extra-terminal domain); BRDs (bromodomains); DNMTs (DNA methyltransferases); ncRNA (non-coding RNA); lncRNA (long non-coding RNA); miRNA (microRNA); Dicer (Endoribonuclease Dicer C-terminal complex); TET (ten-eleven translocation); 2OG (2Oxoglutarate Oxygenase); IOX-1 (Histone demethylase inhibitor); Risc (RNA-induced silencing complex); T h17 cells (T helper 17 cells); the symbol “?” indicates that the mechanism has not yet been clarified.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 22

Metadata

Authors
Sisto, M., & Lisi, S.
Affiliations
University of Bari Aldo Moro (IT)
Corresponding author
Sisto, Margherita
Venue
Journal of Clinical Medicine
Publisher
MDPI AG
Published
2023-12-27
Volume
13
Issue
1
Pages
164
ISSN
2077-0383 (ISSN-L)
OpenAlex
W4390265558
Cited by
22
References
136
Citations by year
2026: 6 · 2025: 12 · 2024: 3 · 2023: 1
FWCI
0.61
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Medicine (publishedVersion, cc-by)
  • Preprints.org (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, cc-by)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
Keywords
IL-17, fibrotic diseases, fibrosis, antifibrotic therapy, chronic inflammation, epigenetic regulation, IL-17 signaling, organ failure, autoimmune disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.